NCT04157985 2025-12-11Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsUniversity of PittsburghPhase 3 Completed161 enrolled
NCT03693014 2025-10-06A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting69 enrolled
NCT03289962 2025-07-04A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsGenentech, Inc.Phase 1 Completed272 enrolled
NCT03024437 2025-03-20Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell CarcinomaIndiana UniversityPhase 1/2 Terminated31 enrolled 19 charts
NCT02724878 2025-02-13Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaDana-Farber Cancer InstitutePhase 2 Completed65 enrolled 30 charts
NCT02655822 2021-08-30Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersCorvus Pharmaceuticals, Inc.Phase 1 Completed502 enrolled
NCT02543645 2018-04-30A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerCelldex TherapeuticsPhase 1 Terminated18 enrolled